Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040562 | 1.00 | POLB (0.58) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3042280 | 0.99 | ALDH1A1 (0.58) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL2793876 | 0.94 | HTT (0.64) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3048703 | 0.93 | HTT (0.62) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3044988 | 0.87 | POLB (0.55) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3044573 | 0.87 | POLB (0.55) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3677123 | 0.87 | ALDH1A1 (0.46) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3673737 | 0.87 | ALDH1A1 (0.46) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3034639 | 0.86 | ALDH1A1 (0.55) | POLBHTTALDH1A1CHRM2CHRM1 | |
| SCHEMBL3049247 | 0.82 | KEAP1 (0.49) | POLBALDH1A1CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | claimed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | claimed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | claimed |
| US-8420810-B2 | Bicyclic heterocyclic compound | Ono Pharmaceutical, Co., Ltd. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100137318-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2154139-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | POLB 3807/4885HTT 2126/4885ALDH1A1 1738/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | POLB 1328/4885HTT 4847/4885ALDH1A1 2460/4885 |
| US-20100137318-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRH, CRHR1, NR3C2 | POLB 3222/4885HTT 2652/4885ALDH1A1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.